Administration of a CXCL12 receptor CXCR4 inhibitor AMD3100 to mice with human pancreatic tumors induces rapid T-cell accumulation among cancer cells and acts synergistically with αPD-L1 to reverse immune suppression and resistance to immune therapy to diminish or eliminate cancer cells and their loss of heterogeneity of transformation related protein 53 (TRP53) [541]. Here, TP53 is linked to pancreatic neoplasm.